FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Dale Schenk

Research Profile

Chemicals & Drugs

Disorders

Living Beings

Co-author Network

Publications

TOP 3
Sean A Pintchovski; Dale Schenk; Guriqbal S Basi
Evidence that enzyme processivity mediates differential Aβ production by PS1 and PS2.
Frédérique Bard; Michael Fox; Stuart Friedrich; Gene G Kinney; Dale Schenk; Peter Seubert; Ted Yednock
Sustained levels of antibodies against Aβ in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice.
Dale Schenk; Guriqbal S Basi; Menelas N Pangalos
Treatment strategies targeting amyloid β-protein.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Dale Schenk (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Sean A Pintchovski; Dale Schenk; Guriqbal S Basi
Evidence that enzyme processivity mediates differential Aβ production by PS1 and PS2.
Current Alzheimer research 2013;10(1):4-10.
2012: Frédérique Bard; Michael Fox; Stuart Friedrich; Gene G Kinney; Dale Schenk; Peter Seubert; Ted Yednock
Sustained levels of antibodies against Aβ in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice.
Experimental neurology 2012;238(1):38-43.
2012: Dale Schenk; Guriqbal S Basi; Menelas N Pangalos
Treatment strategies targeting amyloid β-protein.
Cold Spring Harbor perspectives in medicine 2012;2(9):a006387.
2012: Wagner Zago; Christopher Nishioka; Dale Schenk; Peter Seubert; Frédérique Bard; Manuel Buttini; Thomas A Comery; Dora Games; Shyra J Gardai; Gene G Kinney
Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2012;32(8):2696-702.
2011: Eliezer Masliah; Edward Rockenstein; Michael Mante; Leslie Crews; Brian Spencer; Anthony Adame; Christina Patrick; Margarita Trejo; Kiren Ubhi; Troy T Rohn; Sarah Mueller-Steiner; Peter Seubert; Robin Barbour; Lisa McConlogue; Manuel Buttini; Dora Games; Dale Schenk
Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease.
PloS one 2011;6(4):e19338.
2011: Steven T DeKosky; Maria C Carrillo; Creighton Phelps; David S. Knopman; Ronald C. Petersen; Richard Frank; Dale Schenk; Donna Masterman; Eric R Siemers; Jesse M Cedarbaum; Michael Gold; David S Miller; Bruce H Morimoto; Ara S Khachaturian; Richard C Mohs
Revision of the criteria for Alzheimer’s disease: A symposium.
Alzheimer's & dementia : the journal of the Alzheimer's Association 2011;7(1):e1-12.
2010: Dale Schenk
Introduction to the special issue of Experimental Neurology on Alzheimer's disease.
Experimental neurology 2010;223(2):251.
2010: Juha O Rinne; David J Brooks; Martin N Rossor; Nick C Fox; Roger Bullock; William E Klunk; Chester A Mathis; Kaj Blennow; Jerome Barakos; Aren A Okello; Sofia Rodriguez Martinez de Liano; Enchi Liu; Martin Koller; Keith M Gregg; Dale Schenk; Ronald Black; Michael Grundman
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.
Lancet neurology 2010;9(4):363-72.
2010: Guriqbal S Basi; Hadar Feinberg; Farshid Oshidari; John Anderson; Robin Barbour; Jeanne Baker; Thomas A Comery; Linnea Diep; Davinder Gill; Kelly Johnson-Wood; Amita Goel; Katerina Grantcharova; Mike Lee; Jingzhi Li; Anthony Partridge; Irene Griswold-Prenner; Nicolas Piot; Don Walker; Angela Widom; Menelas Pangalos; Peter Seubert; J Steven Jacobsen; Dale Schenk; William I Weis
Structural correlates of antibodies associated with acute reversal of amyloid beta-related behavioral deficits in a mouse model of Alzheimer disease.
The Journal of biological chemistry 2010;285(5):3417-27.
2010: Guriqbal S Basi; Susanna Hemphill; Elizabeth F Brigham; Anna Liao; Danielle L Aubele; Jeanne Baker; Robin Barbour; Michael Bova; Xiao-Hua Chen; Michael S Dappen; Tovah Eichenbaum; Erich Goldbach; Jon Hawkinson; Rose Lawler-Herbold; Kang Hu; Terence Hui; Jacek J Jagodzinski; Pamela S Keim; Dora Kholodenko; Lee H Latimer; Mike Lee; Jennifer Marugg; Matthew N Mattson; Scott McCauley; James L Miller; Ruth Motter; Linda Mutter; Martin L Neitzel; Huifang Ni; Lan Nguyen; Kevin Quinn; Lany Ruslim; Christopher M Semko; Paul Shapiro; Jenifer Smith; Ferdie Soriano; Balazs Szoke; Kevin Tanaka; Pearl Tang; John A Tucker; Xiacong Michael Ye; Mei Yu; Jing Wu; Ying-Zi Xu; Albert W Garofalo; John-Michael Sauer; Andrei W Konradi; Daniel Ness; George Shopp; Michael A Pleiss; Stephen B Freedman; Dale Schenk
Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease.
Alzheimer's research & therapy 2010;2(6):36.
2009: Stephen Salloway; R Sperling; Sid Gilman; Nick C Fox; Kaj Blennow; M Raskind; Marwan Sabbagh; Lawrence Honig; Rachelle S Doody; C H van Dyck; R Mulnard; J Barakos; K M Gregg; E Liu; I Lieberburg; Dale Schenk; R Black; M Grundman
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.
Neurology 2009;73(24):2061-70.
2009: Kaoru Yamada; Chiori Yabuki; Peter Seubert; Dale Schenk; Yukiko Hori; Sumio Ohtsuki; Tetsuya Terasaki; Tadafumi Hashimoto; Takeshi Iwatsubo
Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2009;29(36):11393-8.
2009: Christofer Lendel; CARLOS WALTER BERTONCINI; Nunilo Cremades; Christopher Waudby; Michele Vendruscolo; Christopher M Dobson; Dale Schenk; John Christodoulou; Gergely Toth
On the mechanism of nonspecific inhibitors of protein aggregation: dissecting the interactions of alpha-synuclein with Congo red and lacmoid.
Biochemistry 2009;48(35):8322-34.
2009: Maria C Carrillo; Andrew Blackwell; Harald Hampel; Johan Lindborg; Reisa Sperling; Dale Schenk; Jeffrey J Sevigny; Steven Ferris; David A Bennett; Suzanne Craft; Timothy Hsu; William E Klunk
Early risk assessment for Alzheimer's disease.
Alzheimer's & dementia : the journal of the Alzheimer's Association 2009;5(2):182-96.
2009: ZAVEN KHACHATURIAN; Peter J Snyder; Rachelle S Doody; Paul S Aisen; Meryl Comer; John Dwyer; Richard A Frank; Andrew Holzapfel; Ara Khachaturian; Amos D Korczyn; Allen D Roses; James W Simpkins; Lon S Schneider; Marilyn S Albert; Robert Egge; Aaron Deves; Steven Ferris; Barry D Greenberg; Carl Johnson; Walter A Kukull; Judes Poirier; Dale Schenk; William Thies; S Gauthier; Sid Gilman; Charles Bernick; Jeffrey L Cummings; Howard Fillit; Michael Grundman; Jeffrey A Kaye; Lennart Mucke; Barry Reisberg; Mary Sano; Oxana Pickeral; Ronald C. Petersen; Richard C Mohs; Maria Carrillo; Jody Corey-Bloom; Norman L Foster; Steve Jacobsen; Virginia M-Y Lee; William Z Potter; Marwan Sabbagh; David P Salmon; John Q Trojanowski; Nancy Wexler; Lisa J Bain
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.
Alzheimer's & dementia : the journal of the Alzheimer's Association 2009;5(2):85-92.
2009: Tara L Spires-Jones; Matthew L Mielke; Anete Rozkalne; Melanie Meyer-Luehmann; Alix de Calignon; Brian J Bacskai; Dale Schenk; Bradley T Hyman
Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease.
Neurobiology of disease 2009;33(2):213-20.
2008: Sally Schroeter; Karen Khan; Robin Barbour; Minhtam Doan; Ming Chen; Terry Guido; Davinder Gill; Guriqbal Basi; Dale Schenk; Peter Seubert; Dora Games
Immunotherapy reduces vascular amyloid-beta in PDAPP mice.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2008;28(27):6787-93.
2008: ZAVEN KHACHATURIAN; Ronald C. Petersen; S Gauthier; Neil Buckholtz; Jody Corey-Bloom; Bill Evans; Howard Fillit; Norman Foster; Barry Greenberg; Michael Grundman; Mary Sano; James Simpkins; Lon S Schneider; Michael Weiner; Douglas Galasko; Bradley T Hyman; Lew Kuller; Dale Schenk; Stephen Snyder; Ronald Thomas; Mark H Tuszynski; Bruno Vellas; Richard J Wurtman; Peter J Snyder; Richard A Frank; Marilyn S Albert; Rachelle S Doody; Steven H Ferris; Jeffrey A Kaye; Edward H Koo; Marcelle Morrison-Bogorad; Barry Reisberg; David P Salmon; Sid Gilman; Richard C Mohs; Paul S Aisen; John C S Breitner; Jeffrey L Cummings; Claudia Kawas; Creighton Phelps; Judes Poirier; Marwan Sabbagh; Jacques Touchon; Ara Khachaturian; Lisa J Bain
A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium.
Alzheimer's & dementia : the journal of the Alzheimer's Association 2008;4(3):156-63.
2008: Dale Schenk
Commentary on "New directions for frontotemporal dementia drug discovery." Do we know enough to develop meaningful treatments for frontotemporal dementia?
Alzheimer's & dementia : the journal of the Alzheimer's Association 2008;4(2):94-5.
2008: Byron Zhao; Mei Yu; Martin Neitzel; Jennifer Marugg; Jacek Jagodzinski; Mike Lee; Kang Hu; Dale Schenk; Ted Yednock; Guriqbal S Basi
Identification of gamma-secretase inhibitor potency determinants on presenilin.
The Journal of biological chemistry 2008;283(5):2927-38.
2008: Dale Schenk
Current challenges for the successful treatment and prevention of Alzheimer's disease: treating the pathologies of the disease to change its clinical course.
Alzheimer's & dementia : the journal of the Alzheimer's Association 2008;4(1 Suppl 1):S119-21.
2008: Peter Seubert; Robin Barbour; Karen Khan; Ruth Motter; Pearl Tang; Dora Kholodenko; Kristin Kling; Dale Schenk; Kelly Johnson-Wood; Sally Schroeter; Davinder Gill; J Steven Jacobsen; Menelas Pangalos; Guriqbal S Basi; Dora Games
Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse.
Neuro-degenerative diseases 2008;5(2):65-71.
2007: Zhao Ren; Dale Schenk; Guriqbal S Basi; I Paul Shapiro
Amyloid beta-protein precursor juxtamembrane domain regulates specificity of gamma-secretase-dependent cleavages.
The Journal of biological chemistry 2007;282(48):35350-60.
2006: Nicoll James; Edward Barton; Delphine Boche; Jim W Neal; Isidro Ferrer; Petrina Thompson; Christina Vlachouli; David Wilkinson; Antony Bayer; Dora Games; Peter Seubert; Dale Schenk; Clive Holmes
Abeta species removal after abeta42 immunization.
Journal of neuropathology and experimental neurology 2006;65(11):1040-8.
2006: Marion Buckwalter; Bronwen S Coleman; Manuel Buttini; Robin Barbour; Dale Schenk; Dora Games; Peter Seubert; Tony Wyss-Coray
Increased T cell recruitment to the CNS after amyloid beta 1-42 immunization in Alzheimer's mice overproducing transforming growth factor-beta 1.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2006;26(44):11437-41.
2006: John P Anderson; Donald E Walker; Jason Goldstein; Rian de Laat; Kelly Banducci; Russell J Caccavello; Robin Barbour; Jiping Huang; Kristin Kling; Michael Lee; Linnea Diep; Pamela S Keim; Xiaofeng Shen; Tim Chataway; Michael G Schlossmacher; Peter Seubert; Dale Schenk; Sukanto Sinha; Wei Ping Gai; Tamie J Chilcote
Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease.
The Journal of biological chemistry 2006;281(40):29739-52.
2006: Dale Schenk; Maria C Carrillo; John Q Trojanowski
Cytoskeletal modulators and pleiotropic strategies for Alzheimer drug discovery.
Alzheimer's & dementia : the journal of the Alzheimer's Association 2006;2(4):275-81.
2006: Michael Grundman; Ronald C. Petersen; David A Bennett; Howard H Feldman; Stephen Salloway; Pieter Jelle Visser; Leon J Thal; Dale Schenk; ZAVEN KHACHATURIAN; William Thies
Alzheimer's Association Research Roundtable Meeting on Mild Cognitive Impairment: what have we learned?
Alzheimer's & dementia : the journal of the Alzheimer's Association 2006;2(3):220-33.
2006: Dale Schenk
Treatment of Alzheimer's disease: the beginning of a new era.
Current Alzheimer research 2006;3(3):177.
2006: Dale Schenk; Sid Gilman
What do people at risk for Alzheimer disease think about surrogate consent for research?
Neurology 2006;66(11):1785-6.
2006: Dora Games; Manuel Buttini; Dione Kobayashi; Dale Schenk; Peter Seubert
Mice as models: transgenic approaches and Alzheimer's disease.
Journal of Alzheimer's disease : JAD 2006;9(3 Suppl):133-49.
2006: Leon J Thal; Kejal Kantarci; Eric Reiman; William E Klunk; Michael Weiner; Henrik Zetterberg; Douglas Galasko; Domenico Pratico'; Sue Griffin; Dale Schenk; Eric Siemers
The role of biomarkers in clinical trials for Alzheimer disease.
Alzheimer disease and associated disorders 2006;20(1):6-15.
2005: Chera Esh; Lyle Patton; Walter Kalback; Tyler A Kokjohn; John Lopez; Daniel C Brune; Amanda Newell; Thomas Beach; Dale Schenk; Dora Games; Steven Paul; Kelly Bales; Bernardino Ghetti; Eduardo M Castaño; Alex Roher
Altered APP processing in PDAPP (Val717 --> Phe) transgenic mice yields extended-length Abeta peptides.
Biochemistry 2005;44(42):13807-19.
2005: Manuel Buttini; Eliezer Masliah; Robin Barbour; Henry Grajeda; Ruth Motter; Kelly Johnson-Wood; Karen Khan; Peter Seubert; Stephen Freedman; Dale Schenk; Dora Games
Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2005;25(40):9096-101.
2005: Michael Lee; Frédérique Bard; Kelly Johnson-Wood; Celeste Lee; Kang Hu; Sue G Griffith; Ronald S Black; Dale Schenk; Peter Seubert
Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies.
Annals of neurology 2005;58(3):430-5.
2005: Eliezer Masliah; Edward Rockenstein; Anthony Adame; Michael Alford; Leslie Crews; Makoto Hashimoto; Peter Seubert; Michael Lee; Jason Goldstein; Tamie J Chilcote; Dora Games; Dale Schenk
Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.
Neuron 2005;46(6):857-68.
2005: Nikolay L Malinin; Sarah Wright; Peter Seubert; Dale Schenk; Irene Griswold-Prenner
Amyloid-beta neurotoxicity is mediated by FISH adapter protein and ADAM12 metalloprotease activity.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(8):3058-63.
2005: Eliezer Masliah; Lawrence A Hansen; Anthony Adame; Leslie Crews; Frédérique Bard; C Lee; Peter Seubert; Dora Games; L Kirby; Dale Schenk
Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease.
Neurology 2005;64(1):129-31.
2005: Dale Schenk; Peter Seubert; Michael Grundman; Ron Black
A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease.
Neuro-degenerative diseases 2005;2(5):255-60.
2004: Dale Schenk; Michael Hagen; Peter Seubert
Current progress in beta-amyloid immunotherapy.
Current opinion in immunology 2004;16(5):599-606.
2004: Dale Schenk
Hopes remain for an Alzheimer's vaccine.
Nature 2004;431(7007):398.
2004: Joseph Krezowski; Danielle Knudson; Christine Ebeling; Rose Pitstick; Ranjit K Giri; Dale Schenk; David Westaway; Linda Younkin; Steven G Younkin; Karen K. Hsiao Ashe; George A Carlson
Identification of loci determining susceptibility to the lethal effects of amyloid precursor protein transgene overexpression.
Human molecular genetics 2004;13(18):1989-97.
2004: Thierry Bussière; Frédérique Bard; Robin Barbour; Henry Grajeda; Terry Guido; Karen Khan; Dale Schenk; Dora Games; Peter Seubert; Manuel Buttini
Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance.
The American journal of pathology 2004;165(3):987-95.
2004: Chi-Cheng Wu; Faisal Chawla; Dora Games; Russell E Rydel; Stephen Freedman; Dale Schenk; Warren G Young; John H Morrison; Floyd E Bloom
Selective vulnerability of dentate granule cells prior to amyloid deposition in PDAPP mice: digital morphometric analyses.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(18):7141-6.
2003: John F Reilly; Dora Games; Russell E Rydel; Stephen Freedman; Dale Schenk; Warren G Young; John H Morrison; Floyd E Bloom
Amyloid deposition in the hippocampus and entorhinal cortex: quantitative analysis of a transgenic mouse model.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(8):4837-42.
2003: Frédérique Bard; Robin Barbour; Catherine Cannon; Robert Carretto; Michael Fox; Dora Games; Terry Guido; Kathleen Hoenow; Kang Hu; Kelly Johnson-Wood; Karen Khan; Dora Kholodenko; Celeste Lee; Mike Lee; Ruth Motter; Minh Nguyen; Amanda Reed; Dale Schenk; Pearl Tang; Nicki Vasquez; Peter Seubert; Ted Yednock
Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(4):2023-8.
2003: Dennis J Selkoe; Dale Schenk
Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics.
Annual review of pharmacology and toxicology 2003;43():545-84.
2002: Dale Schenk
Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning.
Nature reviews. Neuroscience 2002;3(10):824-8.
2002: Brian J Bacskai; Stephen T Kajdasz; Megan E McLellan; Dora Games; Peter Seubert; Dale Schenk; Bradley T Hyman
Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2002;22(18):7873-8.
2002: Dale Schenk; Ted Yednock
The role of microglia in Alzheimer's disease: friend or foe?
Neurobiology of aging 2002;23(5):677-9; discussion 683-4.
2001: Dale Schenk; Peter Seubert; R B Ciccarelli
Immunotherapy with beta-amyloid for Alzheimer's disease: a new frontier.
DNA and cell biology 2001;20(11):679-81.
2001: Dale Schenk; Dora Games; Peter Seubert
Potential treatment opportunities for Alzheimer's disease through inhibition of secretases and Abeta immunization.
Journal of molecular neuroscience : MN 2001;17(2):259-67.
2001: David J Brayden; L Templeton; Siobhán McClean; Robin Barbour; J Huang; M Nguyen; D Ahern; Ruth Motter; Kelly Johnson-Wood; Nicki Vasquez; Dale Schenk; Peter Seubert
Encapsulation in biodegradable microparticles enhances serum antibody response to parenterally-delivered beta-amyloid in mice.
Vaccine 2001;19(30):4185-93.
2001: Steven Roberds; J Anderson; G Basi; M J Bienkowski; D G Branstetter; K S Chen; S B Freedman; N L Frigon; D Games; K Hu; K Johnson-Wood; K E Kappenman; T T Kawabe; I Kola; R Kuehn; M Lee; W Liu; R Motter; N F Nichols; M Power; D W Robertson; Dale Schenk; M Schoor; G M Shopp; M E Shuck; S Sinha; K A Svensson; G Tatsuno; H Tintrup; J Wijsman; S Wright; L McConlogue
BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics.
Human molecular genetics 2001;10(12):1317-24.
2001: Nagahisa Oshima; Maho Morishima-Kawashima; Haruyasu Yamaguchi; M Yoshimura; S Sugihara; K Khan; Dora Games; Dale Schenk; Yasuo Ihara
Accumulation of amyloid beta-protein in the low-density membrane domain accurately reflects the extent of beta-amyloid deposition in the brain.
The American journal of pathology 2001;158(6):2209-18.
2001: Brian J Bacskai; Stephen T Kajdasz; Richard Christie; C Carter; Dora Games; Peter Seubert; Dale Schenk; Bradley T Hyman
Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy.
Nature medicine 2001;7(3):369-72.
2001: H F Dovey; V John; J P Anderson; L Z Chen; P de Saint Andrieu; L Y Fang; S B Freedman; B Folmer; E Goldbach; Elzbieta Holsztynska; K L Hu; K L Johnson-Wood; S L Kennedy; D Kholodenko; J E Knops; L H Latimer; Michael K Lee; Z Liao; I Lieberburg; R N Motter; L C Mutter; J Nietz; K P Quinn; K L Sacchi; Peter Seubert; G M Shopp; E D Thorsett; jay tung; J Wu; S Yang; C T Yin; Dale Schenk; Patrick May; L D Altstiel; M H Bender; L N Boggs; T C Britton; J C Clemens; D L Czilli; D K Dieckman-McGinty; J J Droste; K S Fuson; B D Gitter; P A Hyslop; E M Johnstone; W Y Li; S P Little; T E Mabry; F D Miller; J E Audia
Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain.
Journal of neurochemistry 2001;76(1):173-81.
2000: Dale Schenk
Alzheimer's disease. A partner for presenilin.
Nature 2000;407(6800):34-5.
2000: Frédérique Bard; C Cannon; Robin Barbour; R L Burke; Dora Games; Henry Grajeda; Terry Guido; Kang Hu; Jiping Huang; Kelly Johnson-Wood; Karen Khan; Dora Kholodenko; Mike Lee; I Lieberburg; Ruth Motter; M Nguyen; F Soriano; Nicki Vasquez; K Weiss; B Welch; Peter Seubert; Dale Schenk; Ted Yednock
Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease.
Nature medicine 2000;6(8):916-9.
2000: Dale Schenk; Peter Seubert; I Lieberburg; J Wallace
beta-peptide immunization: a possible new treatment for Alzheimer disease.
Archives of neurology 2000;57(7):934-6.
2000: Dora Games; Frédérique Bard; Henry Grajeda; Terry Guido; K Khan; F Soriano; Nicki Vasquez; N Wehner; Kelly Johnson-Wood; Ted Yednock; Peter Seubert; Dale Schenk
Prevention and reduction of AD-type pathology in PDAPP mice immunized with A beta 1-42.
Annals of the New York Academy of Sciences 2000;920():274-84.
2000: Sukanto Sinha; J Anderson; Varghese John; Lisa McConlogue; Guriqbal S Basi; Eugene D Thorsett; Dale Schenk
Recent advances in the understanding of the processing of APP to beta amyloid peptide.
Annals of the New York Academy of Sciences 2000;920():206-8.
1999: Sukanto Sinha; John P Anderson; Robin Barbour; Guriqbal S Basi; R Caccavello; D Davis; M Doan; H F Dovey; Normand Frigon; J Hong; K Jacobson-Croak; Nancy E Jewett; P Keim; J Knops; I Lieberburg; M Power; H Tan; G Tatsuno; jay tung; Dale Schenk; Peter Seubert; S M Suomensaari; S Wang; D Walker; J Zhao; Lisa McConlogue; Varghese John
Purification and cloning of amyloid precursor protein beta-secretase from human brain.
Nature 1999;402(6761):537-40.
1999: Dale Schenk; Robin Barbour; W Dunn; Grace Gordon; Henry Grajeda; Terry Guido; Kang Hu; Jiping Huang; Kelly Johnson-Wood; Karen Khan; Dora Kholodenko; Mike Lee; Z Liao; I Lieberburg; Ruth Motter; L Mutter; F Soriano; G Shopp; Nicki Vasquez; C Vandevert; S Walker; Mark Wogulis; Ted Yednock; Dora Games; Peter Seubert
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.
Nature 1999;400(6740):173-7.
1999: M Enya; Maho Morishima-Kawashima; M Yoshimura; Y Shinkai; K Kusui; K Khan; Dora Games; Dale Schenk; S Sugihara; Haruyasu Yamaguchi; Yasuo Ihara
Appearance of sodium dodecyl sulfate-stable amyloid beta-protein (Abeta) dimer in the cortex during aging.
The American journal of pathology 1999;154(1):271-9.
1998: Douglas Galasko; L Chang; Ruth Motter; C M Clark; Jeffrey A Kaye; David S. Knopman; R Thomas; Dora Kholodenko; Dale Schenk; I Lieberburg; Bruce L Miller; Ralph Green; R Basherad; L Kertiles; M A Boss; Peter Seubert
High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.
Archives of neurology 1998;55(7):937-45.
1998: Christoph Hock; S Golombowski; Franz Müller-Spahn; W Naser; Konrad Beyreuther; U Mönning; Dale Schenk; C Vigo-Pelfrey; Ashley I Bush; Robert D. Moir; Rudolph E Tanzi; John H Growdon; Roger M Nitsch
Cerebrospinal fluid levels of amyloid precursor protein and amyloid beta-peptide in Alzheimer's disease and major depression - inverse correlation with dementia severity.
European neurology 1998;39(2):111-8.
1997: Michael C Irizarry; F Soriano; M McNamara; K J Page; Dale Schenk; Dora Games; Bradley T Hyman
Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse.
The Journal of neuroscience : the official journal of the Society for Neuroscience 1997;17(18):7053-9.
1997: T Gómez-Isla; Wilma Wasco; W P Pettingell; S Gurubhagavatula; S D Schmidt; P D Jondro; MJ McNamara; L A Rodes; T DiBlasi; Whitfield B Growdon; Peter Seubert; Dale Schenk; John H Growdon; Bradley T Hyman; Rudolph E Tanzi
A novel presenilin-1 mutation: increased beta-amyloid and neurofibrillary changes.
Annals of neurology 1997;41(6):809-13.
1997: Kelly Johnson-Wood; Mike Lee; Ruth Motter; Kang Hu; Grace Gordon; Robin Barbour; Karen Khan; M Gordon; H Tan; Dora Games; I Lieberburg; Dale Schenk; Peter Seubert; Lisa McConlogue
Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(4):1550-5.
1997: Martin Citron; David Westaway; Weiming Xia; G Carlson; Thekla S Diehl; Georges Levesque; Kelly Johnson-Wood; Mike Lee; Peter Seubert; A Davis; Dora Kholodenko; Ruth Motter; R Sherrington; B Perry; H Yao; R Strome; I Lieberburg; Johanna M Rommens; S Kim; Dale Schenk; Paul E Fraser; Peter St George-Hyslop; Dennis J Selkoe
Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice.
Nature medicine 1997;3(1):67-72.
1996: Dale Schenk; I Lieberburg; Ruth Motter; Peter Seubert
The effect of apolipoprotein E genotype on biochemical markers of Alzheimer's disease.
Annals of the New York Academy of Sciences 1996;802():92-100.
1996: Eliezer Masliah; Abbyann Sisk; Margaret Mallory; Lennart Mucke; Dale Schenk; Dora Games
Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease.
The Journal of neuroscience : the official journal of the Society for Neuroscience 1996;16(18):5795-811.
1996: Lisa McConlogue; F Castellano; C deWit; Dale Schenk; William Maltese
Differential effects of a Rab6 mutant on secretory versus amyloidogenic processing of Alzheimer's beta-amyloid precursor protein.
The Journal of biological chemistry 1996;271(3):1343-8.
1995: Christian Haass; Cynthia A Lemere; Anja Capell; Martin Citron; Peter Seubert; Dale Schenk; Lars Lannfelt; Dennis J Selkoe
The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway.
Nature medicine 1995;1(12):1291-6.
1995: Lars Lannfelt; Hans Basun; C Vigo-Pelfrey; Lars-Olof Wahlund; Bengt Winblad; I Lieberburg; Dale Schenk
Amyloid beta-peptide in cerebrospinal fluid in individuals with the Swedish Alzheimer amyloid precursor protein mutation.
Neuroscience letters 1995;199(3):203-6.
1995: Dale Schenk; Russell E Rydel; P May; S Little; J Panetta; I Lieberburg; S Sinha
Therapeutic approaches related to amyloid-beta peptide and Alzheimer's disease.
Journal of medicinal chemistry 1995;38(21):4141-54.
1995: Peter Seubert; M Mawal-Dewan; Robin Barbour; R Jakes; Michel Goedert; Gail Johnson; J M Litersky; Dale Schenk; I Lieberburg; John Q Trojanowski
Detection of phosphorylated Ser262 in fetal tau, adult tau, and paired helical filament tau.
The Journal of biological chemistry 1995;270(32):18917-22.
1995: Dale Schenk; K D Games; Lisa McConlogue
The potential utility of transgenic mice harboring beta-amyloid precursor protein.
Neurobiology of aging 1995;16(4):711-3; discussion 715-8.
1995: W C Wallace; I Lieberburg; Dale Schenk; C Vigo-Pelfrey; Kenneth L Davis; Vahram Haroutunian
Chronic elevation of secreted amyloid precursor protein in subcortically lesioned rats, and its exacerbation in aged rats.
The Journal of neuroscience : the official journal of the Society for Neuroscience 1995;15(7 Pt 1):4896-905.
1995: Roger M Nitsch; G. William Rebeck; M Deng; U I Richardson; M Tennis; Dale Schenk; C Vigo-Pelfrey; I Lieberburg; Richard Jay Wurtman; Bradley T Hyman
Cerebrospinal fluid levels of amyloid beta-protein in Alzheimer's disease: inverse correlation with severity of dementia and effect of apolipoprotein E genotype.
Annals of neurology 1995;37(4):512-8.
1994: Martin Citron; C Vigo-Pelfrey; David B Teplow; C Miller; Dale Schenk; J Johnston; Bengt Winblad; N Venizelos; Lars Lannfelt; Dennis J Selkoe
Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(25):11993-7.
1994: Janet A Johnston; Richard Frank Cowburn; S Norgren; Birgitta Wiehager; N Venizelos; Bengt Winblad; C Vigo-Pelfrey; Dale Schenk; Lars Lannfelt; C O'Neill
Increased beta-amyloid release and levels of amyloid precursor protein (APP) in fibroblast cell lines from family members with the Swedish Alzheimer's disease APP670/671 mutation.
FEBS letters 1994;354(3):274-8.
1994: Lary Walker; Donald L Price; Mary Lou Voytko; Dale Schenk
Labeling of cerebral amyloid in vivo with a monoclonal antibody.
Journal of neuropathology and experimental neurology 1994;53(4):377-83.
1994: W A van Gool; Dale Schenk; P A Bolhuis
Concentrations of amyloid-beta protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease.
Neuroscience letters 1994;172(1-2):122-4.
1994: Kelly Johnson-Wood; T Henriksson; Peter Seubert; Tilman Oltersdorf; I Lieberburg; Dale Schenk
Identification of secreted beta-amyloid precursor protein binding sites on intact human fibroblasts.
Biochemical and biophysical research communications 1994;200(3):1685-92.
1994: Lars Lannfelt; Nenad Bogdanovic; H Appelgren; Karin Axelman; Lena Lilius; G Hansson; Dale Schenk; John Hardy; Bengt Winblad
Amyloid precursor protein mutation causes Alzheimer's disease in a Swedish family.
Neuroscience letters 1994;168(1-2):254-6.
1993: C Vigo-Pelfrey; D Lee; P Keim; I Lieberburg; Dale Schenk
Characterization of beta-amyloid peptide from human cerebrospinal fluid.
Journal of neurochemistry 1993;61(5):1965-8.
1992: Christian Haass; Michael G Schlossmacher; A Y Hung; C Vigo-Pelfrey; A Mellon; Beth L Ostaszewski; I Lieberburg; Edward H Koo; Dale Schenk; David B Teplow
Amyloid beta-peptide is produced by cultured cells during normal metabolism.
Nature 1992;359(6393):322-5.
1992: Bradley T Hyman; Rudolph E Tanzi; K Marzloff; R Barbour; Dale Schenk
Kunitz protease inhibitor-containing amyloid beta protein precursor immunoreactivity in Alzheimer's disease.
Journal of neuropathology and experimental neurology 1992;51(1):76-83.
1991: J Knops; Kelly Johnson-Wood; Dale Schenk; Sukanto Sinha; I Lieberburg; Lisa McConlogue
Isolation of baculovirus-derived secreted and full-length beta-amyloid precursor protein.
The Journal of biological chemistry 1991;266(11):7285-90.
1989: Larry I Benowitz; W Rodriguez; P Paskevich; Elliott J Mufson; Dale Schenk; R L Neve
The amyloid precursor protein is concentrated in neuronal lysosomes in normal and Alzheimer disease subjects.
Experimental neurology 1989;106(3):237-50.
1989: Tilman Oltersdorf; Lawrence C Fritz; Dale Schenk; I Lieberburg; Kelly Johnson-Wood; E C Beattie; P J Ward; R W Blacher; H F Dovey; Sukanto Sinha
The secreted form of the Alzheimer's amyloid precursor protein with the Kunitz domain is protease nexin-II.
Nature 1989;341(6238):144-7.
1989: T Saitoh; M Sundsmo; J M Roch; N Kimura; Gregory M. Cole; David Schubert; Tilman Oltersdorf; Dale Schenk
Secreted form of amyloid beta protein precursor is involved in the growth regulation of fibroblasts.
Cell 1989;58(4):615-22.
1988: F Fuller; J G Porter; Ann E Arfsten; J Miller; J W Schilling; Robert M Scarborough; J A Lewicki; Dale Schenk
Atrial natriuretic peptide clearance receptor. Complete sequence and functional expression of cDNA clones.
The Journal of biological chemistry 1988;263(19):9395-401.